← All trials
NCT06335407
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2024
- Primary completion
- Sep 30, 2025
- Completion date
- Oct 29, 2025
- First posted
- Mar 28, 2024
- Last posted
- Aug 29, 2024
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharmacotherapies for Alcohol and Substance Abuse ConsortiumLead sponsor
- RTI InternationalCollaborator
- BioXcel Therapeutics IncCollaborator
- Department of Veteran AffairsOfficial
- Department of DefenseCollaborator
- Department of DefenseCollaborator
- Department of Veteran AffairsCollaborator
- Yale UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.